GlassScriptPhysician profile
Jessica Chaumont
NPI 1982095824
$1,902.42
in general payments reported to CMS, 2019-2025
20 companies · $411 in 2025
The $411 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $88.36 · 2022: $293 · 2023: $594 · 2024: $516 · 2025: $411.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,441 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,441.43 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $827.32 | 2021-2025 | |
| Novo Nordisk INC | $160.45 | 2022-2025 | Wegovy, Rybelsus, Ozempic |
| Supernus Pharmaceuticals, INC. | $140.01 | 2023-2025 | Qelbree, Qelbree |
| Axsome Therapeutics, INC. | $127.51 | 2024-2025 | Auvelity |
| Astellas Pharma US INC | $118.22 | 2023-2024 | Veozah |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $92.96 | 2022-2025 | Trulance, Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $85.16 | 2022-2023 | Entyvio |
| Lilly USA, LLC | $73.44 | 2023-2025 | Mounjaro, Zepbound |
| Vanda Pharmaceuticals INC. | $38.91 | 2024-2025 | Fanapt, Hetlioz |
| Pfizer INC. | $33.47 | 2021-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $33.40 | 2022 | |
| Abbott Laboratories | $29.86 | 2022-2023 | Freestyle Libre 2 |
| Ironshore Pharmaceuticals INC. | $28.30 | 2024 | |
| Otsuka America Pharmaceutical, INC. | $24.74 | 2021-2022 | |
| Amgen INC. | $15.94 | 2023 | Otezla, Repatha |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $15.77 | 2025 | Aristada, Lybalvi |
| Astrazeneca Pharmaceuticals LP | $14.87 | 2023 | Farxiga |
| Ardelyx, INC. | $14.22 | 2025 | Ibsrela |
| Sumitomo Pharma America, INC. | $13.99 | 2024 | Gemtesa |
| Amarin Pharma, INC. | $13.88 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jessica Chaumont listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.